2024 Annual Meeting | Industry Therapeutic Update from argenx: Consideration of the Treatment Journey in Generalized Myasthenia Gravis (gMG): Perspectives on the Use of VYVGART and VYVGART HYTRULO in Adults With gMG Who Are Anti-Acetylcholine Receptor Antibody (AChR-Ab) Positive

Date Monday 04/15/24

Time 06:00 PM - 08:00 PM MDT Add To Calendar

Location Hyatt Regency | Centennial F-G

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Neelam Goyal, MD, Kelly G. Gwathmey, MD, Nicholas J. Silvestri, MD, FAAN

Topic(s) General Neurology, Autoimmune Neurology

Learning Objectives Join our expert panel as they discuss current topics regarding the use of VYVGART for intravenous infusion and VYVGART HYTRULO for subcutaneous injection in anti-acetylcholine receptor antibody (AChR-Ab) positive generalized myasthenia gravis, including pathophysiology, long-term clinical data, and observational real-world data.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM MDT	Speaker	Industry Therapeutic Update from argenx: Consideration of the Treatment Journey in Generalized Myasthenia Gravis (gMG): Perspectives on the Use of VYVGART and VYVGART HYTRULO in Adults With gMG Who Are Anti-Acetylcholine Receptor Antibody Positive

Faculty Disclosures
Neelam Goyal, MD	Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Goyal has received research support from Argenx.
Kelly G. Gwathmey, MD	Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Strongbridge. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Gwathmey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals.
Nicholas J. Silvestri, MD, FAAN	Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Strongbridge. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Silvestri has received publishing royalties from a publication relating to health care.